The investigations of postmortem brains from AD patients have revealed that altered sphingolipid metabolism, including the decreased expression of SK1 and the increased expression of S1PL, and, consequently, decreased S1P, may promote AD pathogenesis [9]. Here, SGPL1 is linked to Alzheimer disease.